Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RNXT 
RenovoRx Inc (RNXT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: RNXT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.62
1 Year Target Price $5.62
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.58% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.68M USD | Price to earnings Ratio - | 1Y Target Price 5.62 |
Price to earnings Ratio - | 1Y Target Price 5.62 | ||
Volume (30-day avg) 4 | Beta 1.3 | 52 Weeks Range 0.75 - 1.69 | Updated Date 10/14/2025 |
52 Weeks Range 0.75 - 1.69 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -634.6% |
Management Effectiveness
Return on Assets (TTM) -54.82% | Return on Equity (TTM) -107.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34486272 | Price to Sales(TTM) 61.45 |
Enterprise Value 34486272 | Price to Sales(TTM) 61.45 | ||
Enterprise Value to Revenue 52.09 | Enterprise Value to EBITDA -4.72 | Shares Outstanding 36645884 | Shares Floating 30083339 |
Shares Outstanding 36645884 | Shares Floating 30083339 | ||
Percent Insiders 4.44 | Percent Institutions 24 |
Upturn AI SWOT
RenovoRx Inc
Company Overview
History and Background
RenovoRx Inc. is a biopharmaceutical company founded to develop and commercialize novel therapies for the local treatment of solid tumors. Their focus is on developing targeted therapies to improve outcomes for cancer patients.
Core Business Areas
- Transarterial Micro-Perfusion (TAMPTM) Therapy: RenovoRx's core business revolves around developing and commercializing TAMPTM therapy for delivering therapeutic agents directly to solid tumors. This includes their lead product candidate, RenovoGemTM.
Leadership and Structure
RenovoRx has a leadership team comprised of individuals with experience in pharmaceutical development, commercialization, and finance. The organizational structure is typical for a clinical-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- RenovoGemTM: RenovoGemTM is RenovoRx's lead product candidate, a proprietary formulation of gemcitabine designed for targeted delivery to solid tumors via TAMPTM. It is currently in clinical trials for pancreatic cancer and other solid tumors. Market share is currently 0 as it is not yet approved. Competitors include standard gemcitabine treatments and other chemotherapy regimens for pancreatic cancer.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. There's a growing trend towards personalized medicine and targeted therapies.
Positioning
RenovoRx is positioned as a company focused on targeted drug delivery for solid tumors, differentiating itself through its TAMPTM platform.
Total Addressable Market (TAM)
The TAM for pancreatic cancer treatment is estimated to be billions of dollars globally. RenovoRx is positioned to capture a portion of this market with successful clinical trials and regulatory approval of RenovoGemTM.
Upturn SWOT Analysis
Strengths
- Novel targeted drug delivery platform (TAMPTM)
- Proprietary formulation of gemcitabine (RenovoGemTM)
- Focus on unmet medical needs in solid tumors
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- No currently marketed products
- High regulatory risk
Opportunities
- Positive clinical trial data leading to regulatory approval
- Expansion of TAMPTM platform to other cancer types
- Partnerships with larger pharmaceutical companies
- Increasing prevalence of solid tumors
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established therapies
- Patent challenges
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- GILD
- MRK
- BMY
Competitive Landscape
RenovoRx faces competition from established pharmaceutical companies with approved therapies for solid tumors. Its advantage lies in its targeted drug delivery platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by investment in R&D and expansion of clinical trials.
Future Projections: Future growth is highly dependent on clinical trial success and subsequent commercialization of RenovoGemTM.
Recent Initiatives: Recent initiatives include enrollment in ongoing clinical trials and exploration of potential partnerships.
Summary
RenovoRx is a clinical-stage biopharmaceutical company with a novel targeted drug delivery platform. Success hinges on positive clinical trial data and regulatory approval of RenovoGemTM. The company faces significant financial and regulatory risks common to the industry. Its targeted approach provides a potential competitive advantage if proven effective and safe.
Peer Comparison
Sources and Disclaimers
Data Sources:
- RenovoRx Inc. SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate and based on available industry data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RenovoRx Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-08-26 | CEO, Secretary & Director Mr. Shaun R. Bagai | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://renovorx.com |
Full time employees 10 | Website https://renovorx.com | ||
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.